Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
Catheter Precision, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 19, 2025. The company is incorporated in Delaware and maintains its principal executive offices in Fort Mill, South Carolina. Its common stock trades on the NYSE American under the symbol "VTAK."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on a new financing arrangement.
Material Changes and Agreements
On May 19, 2025, the Company entered into an "At Market Offering Agreement" with Ladenburg Thalmann & Co. Inc. Key terms include:
- Offering Capacity: The Company may offer and sell common stock with an aggregate gross offering price of up to $1.3 million.
- Underwriter: Ladenburg Thalmann & Co. Inc. will act as the sales agent.
- Commission: The Company will pay Ladenburg a commission of 3.0% of the aggregate gross proceeds from each sale.
- Use of Proceeds: Net proceeds, if any, are intended to fund operations and working capital.
- Flexibility: The Company is not obligated to sell any shares and may terminate the agreement with five business days' prior notice.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or outlook beyond the intent to use proceeds for operations. The agreement includes a termination clause allowing Ladenburg to end the arrangement in the event of a material adverse effect on the Company. The document explicitly states that the agreement's representations and warranties are not intended as factual information for investors regarding the Company's current state of affairs.
Investor Verification Checklist
- Verify the current market price of VTAK to assess the potential dilution impact of a $1.3 million offering.
- Review the Company's most recent 10-K or 10-Q to understand current cash reserves and working capital needs.
- Confirm the status of the previously filed Registration Statement on Form S-3 (File No. 333-284217).
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.